a public good project by the
Synthesis
Company
of California

© 2026

Carly M. Bliss | doi.page

0 works0 citations0 h-index

Carly M. Bliss

University of Oxford(GB)Jenner Institute(GB)Cardiff University(GB)

Publications by Year

Research Areas

Malaria Research and Control, Mosquito-borne diseases and control, vaccines and immunoinformatics approaches, Virus-based gene therapy research, HIV Research and Treatment

Most-Cited Works

→ Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain(2012)675 cited
→ A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA(2015)354 cited
→ A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial(2020)347 cited
→ Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species(2012)302 cited
→ A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice(2020)299 cited
→ ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans(2012)224 cited

→ Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults(2015)

131 cited

→ Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals(2014)129 cited

→ Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01_BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP(2016)95 cited

→ First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children(2018)92 cited